<DOC>
	<DOCNO>NCT00900783</DOCNO>
	<brief_summary>The purpose study compare safety efficacy two dose FV-100 valacyclovir patient herpes zoster , shingle . FV-100 show potent cell infect varicella zoster virus , virus cause shingle . The study objective include : - Compare safety FV-100 valacyclovir - Compare effect FV-100 , compare valacyclovir , shingle pain - Compare effect FV-100 , compare valacyclovir , shingle lesion</brief_summary>
	<brief_title>A Study FV-100 Versus Valacyclovir Patients With Herpes Zoster</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>Men woman ≥ 50 year age Patients clinical diagnosis HZ evidence unilateral dermatomal rash Patients zosterrelated pain ( ZBPI worst pain score &gt; 0 ) Patients able enrol study ≤ 72 hour appearance rash ( i.e. , lesion vesicle ) Patients provide write informed consent Patients able complete study visit per protocol Men premenopausal woman must agree practice barrier method birth control plus use spermicide one month last dose study drug ( oral contraceptive permit ) Women pregnant lactating Patients multidermatomal disseminate HZ ( i.e. , &gt; 20 vesicle beyond dermatome adjacent primarily involve dermatome ) Patients HZ ophthalmicus , define cutaneous lesion dermatome associate ophthalmic division trigeminal nerve Patients history impaired renal function , ( e.g. , calculated creatinine clearance &lt; 50 mL/min/1.73 m2 ) Patients take narcotic analgesic routinely chronic pain condition Patients take tricyclic antidepressant Patients receive systemic antiviral activity VZV within past 30 day , topical antiviral treat current HZ Patients immunosuppressed : disease ( e.g. , malignancy [ present remission &lt; 5 year ] , HIV ) corticosteroid use ( except intermittent topical/inhaled beclomethasone dipropionate equivalent &lt; 800 mcg/day ) , immunosuppressive/cytotoxic therapy ( cancer chemotherapy organ transplantation ) Patients gastrointestinal dysfunction could interfere drug absorption Patients condition ( e.g. , extensive psoriasis , chronic pain syndrome , cognitive impairment ) , opinion site investigator , might interfere evaluation require study Patients ambulatory ( bedridden homebound ) ; hospitalize patient may enrol ambulatory able complete study requirement Patients history allergy valacyclovir hydrochloride Patients unlikely adhere protocol followup 14 . Subjects take strong CYP3A4inhibiting protease inhibitor ( specifically include atazanavir , indinavir , nelfinavir , saquinavir , ritonavir ) , strong CYP3A4 inhibitor ( specifically include clarithromycin , itraconazole , ketoconazole , nefazodone , telithromycin ) strong CYP3A4 inducer ( specifically include rifampin , efavirenz , etravirine , phenobarbital , phenytoin , carbamazepine )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>herpes zoster</keyword>
	<keyword>shingle</keyword>
	<keyword>Phase II</keyword>
	<keyword>FV-100</keyword>
	<keyword>Inhibitex</keyword>
</DOC>